Swiss pharma giant Roche (ROG: SIX) presented positive Phase III data on its anti-TIGIT immunotherapy tiragolumab in esophageal cancer this week.
The findings from the SKYSCRAPER-08 study, which were presented in an abstract ahead of the 2024 ASCO Gastrointestinal Cancers Symposium, follow two prior late-stage setbacks for the drug.
But, due to the use of a comparator that is no longer considered the standard of care, there are questions about how important the data are.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze